Real-World ozanimod study tracks RRMS patients for 3 years
NCT ID NCT05335031
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) who were already prescribed ozanimod (Zeposia). Researchers collected real-world data over 3 years to see how long patients stayed on the drug, how it affected their quality of life, and what side effects occurred. The goal was to understand how well the treatment works outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Universitätsklinikum Dresden, MS Ambulanz
Dresden, Saxony, 01307, Germany
Conditions
Explore the condition pages connected to this study.